The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy
Anticancer agents can effectively treat several types of cancers but are often limited in clinical settings due to various adverse effects. In particular, nausea and vomiting are serious side effects that markedly reduce the patients' quality of life. Accordingly, the development of novel antie...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Biochemistry and Biophysics Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580822001637 |
| _version_ | 1828345260424560640 |
|---|---|
| author | Hiroto Yanagawa Yoshihisa Koyama Yuki Kobayashi Hikaru Kobayashi Shoichi Shimada |
| author_facet | Hiroto Yanagawa Yoshihisa Koyama Yuki Kobayashi Hikaru Kobayashi Shoichi Shimada |
| author_sort | Hiroto Yanagawa |
| collection | DOAJ |
| description | Anticancer agents can effectively treat several types of cancers but are often limited in clinical settings due to various adverse effects. In particular, nausea and vomiting are serious side effects that markedly reduce the patients' quality of life. Accordingly, the development of novel antiemetic drugs that lack side effects is crucial, given that most conventional antiemetic drugs are known to possess side effects. In addition, reactive oxygen species generated by anticancer agents are involved in nausea and vomiting; hence, appropriate antioxidants might also be effective toward nausea and vomiting.Silicon (Si)-based agents can abundantly generate antioxidant hydrogen in the intestine. Therefore, we assessed whether Si-based agents could be effective against nausea associated with anticancer agents in cisplatin-injected mice. We observed numerous neurons expressing c-Fos protein, a neuronal activity marker, in the nausea-associated regions of the dorsal medulla (area postrema, nuclei of the solitary tract, and dorsal vagal nuclei) 24 h after cisplatin injection. Conversely, mice fed a diet containing 2.5% Si-based agents showed a reduction in c-Fos-positive neurons.These findings revealed that the Si-based agent alleviated cisplatin-induced nausea. Si-based agents demonstrate potent antioxidant effects by producing hydrogen, which has no known side effects and will be a safer antiemetic agent and greatly help improve the quality of life of patients undergoing anticancer drug treatment. |
| first_indexed | 2024-04-14T00:09:09Z |
| format | Article |
| id | doaj.art-f544eb45e5d24f178d3b24daf696f976 |
| institution | Directory Open Access Journal |
| issn | 2405-5808 |
| language | English |
| last_indexed | 2024-04-14T00:09:09Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biochemistry and Biophysics Reports |
| spelling | doaj.art-f544eb45e5d24f178d3b24daf696f9762022-12-22T02:23:26ZengElsevierBiochemistry and Biophysics Reports2405-58082022-12-0132101363The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapyHiroto Yanagawa0Yoshihisa Koyama1Yuki Kobayashi2Hikaru Kobayashi3Shoichi Shimada4Department of Neuroscience and Cell Biology, Osaka University Graduate School of Medicine, Osaka, 565-0871, JapanDepartment of Neuroscience and Cell Biology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan; Addiction Research Unit, Osaka Psychiatric Research Center, Osaka Psychiatric Medical Center, Osaka, 541-8567, Japan; Corresponding author. Department of Neuroscience and Cell Biology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.Institute of Scientific and Industrial Research, Osaka University, Osaka, 565-0871, JapanInstitute of Scientific and Industrial Research, Osaka University, Osaka, 565-0871, JapanDepartment of Neuroscience and Cell Biology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan; Addiction Research Unit, Osaka Psychiatric Research Center, Osaka Psychiatric Medical Center, Osaka, 541-8567, JapanAnticancer agents can effectively treat several types of cancers but are often limited in clinical settings due to various adverse effects. In particular, nausea and vomiting are serious side effects that markedly reduce the patients' quality of life. Accordingly, the development of novel antiemetic drugs that lack side effects is crucial, given that most conventional antiemetic drugs are known to possess side effects. In addition, reactive oxygen species generated by anticancer agents are involved in nausea and vomiting; hence, appropriate antioxidants might also be effective toward nausea and vomiting.Silicon (Si)-based agents can abundantly generate antioxidant hydrogen in the intestine. Therefore, we assessed whether Si-based agents could be effective against nausea associated with anticancer agents in cisplatin-injected mice. We observed numerous neurons expressing c-Fos protein, a neuronal activity marker, in the nausea-associated regions of the dorsal medulla (area postrema, nuclei of the solitary tract, and dorsal vagal nuclei) 24 h after cisplatin injection. Conversely, mice fed a diet containing 2.5% Si-based agents showed a reduction in c-Fos-positive neurons.These findings revealed that the Si-based agent alleviated cisplatin-induced nausea. Si-based agents demonstrate potent antioxidant effects by producing hydrogen, which has no known side effects and will be a safer antiemetic agent and greatly help improve the quality of life of patients undergoing anticancer drug treatment.http://www.sciencedirect.com/science/article/pii/S2405580822001637Cisplatin chemotherapyNausea and vomitingSi-based agentAntioxidant |
| spellingShingle | Hiroto Yanagawa Yoshihisa Koyama Yuki Kobayashi Hikaru Kobayashi Shoichi Shimada The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy Biochemistry and Biophysics Reports Cisplatin chemotherapy Nausea and vomiting Si-based agent Antioxidant |
| title | The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy |
| title_full | The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy |
| title_fullStr | The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy |
| title_full_unstemmed | The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy |
| title_short | The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy |
| title_sort | development of a novel antioxidant based antiemetic drug to improve quality of life during anticancer therapy |
| topic | Cisplatin chemotherapy Nausea and vomiting Si-based agent Antioxidant |
| url | http://www.sciencedirect.com/science/article/pii/S2405580822001637 |
| work_keys_str_mv | AT hirotoyanagawa thedevelopmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT yoshihisakoyama thedevelopmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT yukikobayashi thedevelopmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT hikarukobayashi thedevelopmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT shoichishimada thedevelopmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT hirotoyanagawa developmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT yoshihisakoyama developmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT yukikobayashi developmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT hikarukobayashi developmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy AT shoichishimada developmentofanovelantioxidantbasedantiemeticdrugtoimprovequalityoflifeduringanticancertherapy |